No Cover Image

Journal article 334 views 71 downloads

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, John Wagstaff, YEN-HWA CHANG, YEN-CHUAN OU, PAUL DONNELLAN, CHAO-YUAN HUANG, JOHN McCAFFREY, PO-HUI CHIANG, CHENG-KENG CHUANG, CAROLINE KORVES, MAUREEN P. NEARY, JOSE R. DIAZ, FAISAL MEHMUD, MEI SHENG DUH

International Journal of Oncology, Volume: 44, Issue: 1, Pages: 5 - 16

Swansea University Author: John Wagstaff

  • 57729.pdf

    PDF | Version of Record

    © Oh et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

    Download (311.06KB)

Check full text

DOI (Published version): 10.3892/ijo.2013.2181

Abstract

The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia...

Full description

Published in: International Journal of Oncology
ISSN: 1019-6439 1791-2423
Published: Spandidos Publications 2013
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa57729
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients ≥18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first‑line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of sunitinib, sorafenib and bevacizumab patients, respectively. Treatment discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% sunitinib, sorafenib and bevacizumab patients, respectively. This study in a large, global cohort of advanced RCC patients found that angiogenesis inhibitors are associated with high rates of AEs and treatment modifications. Findings suggest an unmet need for more tolerable agents for RCC treatment.
Keywords: renal cell carcinoma, angiogenesis inhibitors, safety, treatment patterns, interruption, dose reduction
College: Faculty of Medicine, Health and Life Sciences
Issue: 1
Start Page: 5
End Page: 16

Similar Items